Table I.
Laboratory findings in the sarcoidosis group
| Parameter | Min.–max. | Median | Mean ± SD |
|---|---|---|---|
| Fasting glucose [mg/dl] | 65.0–133.0 | 93.0 | 94.2 ±12.9 |
| Urea [mg/dl] | 11.0–47.0 | 28.0 | 29.3 ±7.6 |
| Creatinine [mg/dl] | 0.4–1.2 | 0.7 | 0.7 ±0.2 |
| AST [IU/l] | 11.0–72.0 | 21.0 | 23.7 ±10.5 |
| ALT [IU/l] | 5.0–102.0 | 21.0 | 25.7 ±18.3 |
| Total cholesterol [mg/dl] | 126–277 | 188 | 192.1 ±36.8 |
| Triglycerides [mg/dl] | 43–398 | 107 | 123.5 ±66.7 |
| HDL [mg/dl] | 27–95 | 50 | 50.1 ±13.1 |
| LDL [mg/dl] | 73–191 | 108 | 117.4 ±28.8 |
| Fe [µg/dl] | 16–147 | 61 | 67.1 ±29.8 |
| HBA1c % | 4.4–7.9 | 5.9 | 6.0 ±0.7 |
| T3 [pg/ml] | 2.4–4.2 | 3.1 | 3.1 ±0.4 |
| T4 [ng/dl] | 0.6–1.2 | 0.9 | 0.9 ±0.1 |
| TSH [uIU] | 0.4–8.7 | 1.9 | 2.4 ±1.6 |
| Sedimentation [mm/h] | 4.0–52.0 | 21.0 | 20.6 ±12.0 |
| WBC [×103/mm3] | 3.0–13.5 | 6.7 | 6.9 ±1.8 |
| RBC [×106/mm3] | 3.8–5.8 | 4.7 | 4.7 ±0.4 |
| ACE levels [U/l] | 5.3–201.0 | 48.7 | 59.2 ±40.8 |
| FEV1 LT | 1.2–5.1 | 2.4 | 2.5 ±0.8 |
| FEV1% pred | 55.0–152.0 | 88.7 | 90.0 ±18.2 |
| FVC LT | 1.9–6.2 | 2.9 | 3.2 ±0.9 |
| FVC % | 51.9–147.0 | 94.0 | 95.0 ±15.7 |
| FEV1/FVC | 2.3–95.9 | 81.4 | 78.5 ±13.0 |
| DLCO | 7.0–42.0 | 22.0 | 21.9 ±7.1 |
| DLCO% | 26.0–140.0 | 80.0 | 84.0 ±21.6 |
| DLCO/VA | 3.6–18.0 | 5.2 | 5.7 ±2.7 |
| DLCO/VA% | 64.0–148.0 | 104.5 | 103.5 ±21.7 |
AST – aspartate aminotransferase, ALT – alanine aminotransferase, HDL – high-density lipoprotein, LDL – low-density lipoprotein, Fe – iron, HBA1c – glycohemoglobin, T3 – free triiodothyronine, T4 – free thyroxine, TSH – thyroid-stimulating hormone, WBC – white blood cell, RBC – red blood cell, ACE levels – angiotensin converting enzyme levels, FEV1 – forced expiratory volume in 1 s, FEV1 % pred – % predicted of forced expiratory volume in 1 s, FVC – forced vital capacity, FVC% pred – % predicted of forced vital capacity, DLCO – diffusing capacity of the lung for carbon monoxide, DLCO/VA – diffusing capacity of the lung for carbon monoxide divided by the alveolar volume.